Browsing tag:

kinase inhibitor


Encouraging news for patients with Melanoma was disseminated on May 7, 2014 with the announcement that Vemurafenib and Cobimetinib look like the next powerful drug duo in the fight against this deadly cancer. Roche and Exelixis revealed that early stage trials of these formidable drugs have shown significant rates of extended survival, with plans underway[…]

Read More

On September 17, 2013 the FDA announced that Breakthrough Status was awarded to Volasertib. Currently marketed by Boehringer Ingelheim, this Volasertib breakthrough designation by the FDA is encouraging for patients suffering from acute myeloid leukemia. Volasertib is unique as it is a selective and powerful polo-like kinase inhibitor. Although Volasertib is currently an unapproved and[…]

Read More

As a kinase inhibitor, Lapatinib Ditosylate, CAS number 388082-78-8 is efficacious when used to treat metastatic breast cancer. The ability of lapatinib ditosylate to inhibit deviating active kinases within cancer cells, and prevent cell division, makes it an effective choice for patients with advanced breast cancer. Also known as Tykerb, which is marketed by GlaxoSmithKline,[…]

Read More

Ruxolitinib, CAS number 941678-49-5, is a kinase inhibitor and used to treat myelofibrosis. The condition of myelofibrosis is one that involves the bone marrow being replaced by scar tissue, therefore causing a decreased blood cell production in patients. Ruxolitinib is effective at blocking the enzymes, janus-associated kinase, or JAK 1 and 2, which causes scar[…]

Read More

In 2009 a new anti-cancer drug, Everolimus, was approved in the US and Europe specifically for use in patients with advanced kidney cancer who were unresponsive to the standard chemotherapy regimen. As a kinase inhibitor, Everolimus effectively inhibits cancer cells from dividing. Since then, the use of Everolimus has extended to treatment of subependymal giant[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service